Monday - April 29, 2024
Buck-Founded Aeovian Pharmaceuticals Doses First Participants in Phase I Trial
March 29, 2024
NOVATO, California, March 29 -- The Buck Institute for Research in Aging issued the following news on March 28, 2024:

Aeovian Pharmaceuticals, a clinical-stage biopharmaceutical company developing novel and highly selective therapeutics that potentially inhibit the mTORC1 pathway, today announced that it has dosed the first cohort of participants for a Phase I study for the treatment of seizures associated with Tuberous Sclerosis Complex. Aeovian also announced they have procured $5 . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products